Influenza A virus subtype H1N1

Antimicrobial Coatings Market worth $7.0 billion by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Wednesday, October 5, 2022
Knowledge, Adoption, SME, Fiberglass, COVID19, Government, Growth, Influenza A virus subtype H1N1, Virus, RPM International, Percussion section, Sherwin-Williams, Bed, AkzoNobel, Air polymer-type A, Final good, Lanxess, CAGR, Intelligence, Commercial, HVAC, Hygiene, Nanoparticle, Research, Nonwoven fabric, Subclinical infection, Eyeish, Industry, Electrostatic precipitator, Food, Health, DSM (company), Row, Electrostatics, GEM, Equipment, Metal, Bacteria, HEPA, Ion, COVID-19, BASF, USD, Consumer, Sika AG, Copper, Heating, ventilation, and air conditioning, Marketing, Automotive industry, Technology, Filtration, Listeria

Silver-based antimicrobial coatings are widely used in various applications because of there have high efficacy against viruses, bacteria, and other eukaryotic microorganisms.

Key Points: 
  • Silver-based antimicrobial coatings are widely used in various applications because of there have high efficacy against viruses, bacteria, and other eukaryotic microorganisms.
  • Silver-based antimicrobial coatings have proven strong inhibitory properties against bacteria and viruses, such as E.coli, H1N1 influenza, and Listeria.
  • The efficacy of silver-based antimicrobial coatings depends on the size and shape of the silver ion used during manufacturing of coatings.
  • North America is also estimated to be the largest market for Antimicrobial coatings Market during the forecast period.

Antimicrobial Coatings Market worth $7.0 billion by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Wednesday, October 5, 2022
Knowledge, Adoption, SME, Fiberglass, COVID19, Government, Growth, Influenza A virus subtype H1N1, Virus, RPM International, Percussion section, Sherwin-Williams, Bed, AkzoNobel, Air polymer-type A, Final good, Lanxess, CAGR, Intelligence, Commercial, HVAC, Hygiene, Nanoparticle, Research, Nonwoven fabric, Subclinical infection, Eyeish, Industry, Electrostatic precipitator, Food, Health, DSM (company), Row, Electrostatics, GEM, Equipment, Metal, Bacteria, HEPA, Ion, COVID-19, BASF, USD, Consumer, Sika AG, Copper, Heating, ventilation, and air conditioning, Marketing, Automotive industry, Technology, Filtration, Listeria

Silver-based antimicrobial coatings are widely used in various applications because of there have high efficacy against viruses, bacteria, and other eukaryotic microorganisms.

Key Points: 
  • Silver-based antimicrobial coatings are widely used in various applications because of there have high efficacy against viruses, bacteria, and other eukaryotic microorganisms.
  • Silver-based antimicrobial coatings have proven strong inhibitory properties against bacteria and viruses, such as E.coli, H1N1 influenza, and Listeria.
  • The efficacy of silver-based antimicrobial coatings depends on the size and shape of the silver ion used during manufacturing of coatings.
  • North America is also estimated to be the largest market for Antimicrobial coatings Market during the forecast period.

Molekule introduces 'Molekule Air Platform' for Businesses

Retrieved on: 
Tuesday, September 27, 2022
Health, MAP, Allergen, COVID-19, FDA, Research, Virus, Severe acute respiratory syndrome coronavirus 2, Organization, Nature, Volatile organic compound, Influenza A virus subtype H1N1, The Home Depot, B2B, PECO, CEO, HVAC, Technology, Clean Air Zone, Solution, Bacteria, SAN, Education, Atmosphere, Right to Clean Air Platform Turkey, Mobile phone, Heating, ventilation, and air conditioning, Fuel oil, H1N1, Molekule, Amazon

SAN FRANCISCO, Sept. 27, 2022 /PRNewswire/ -- Molekule, the leader in reinventing air purification, today announced a new platform for businesses that offers unique insights across multiple air purifiers, called the Molekule Air Platform (MAP). This new dashboard will allow multiple device data and controls to be accessible in one interface, ideal for healthcare, education, business, hospitality, and government settings.

Key Points: 
  • SAN FRANCISCO, Sept. 27, 2022 /PRNewswire/ -- Molekule , the leader in reinventing air purification, today announced a new platform for businesses that offers unique insights across multiple air purifiers, called the Molekule Air Platform (MAP).
  • With our new Molekule Air Platform, we're empowering businesses alike to create 'Clean Air Zones' where users can easily see and manage the air quality of their space, and office managers can see detailed and actionable insights to make air quality improvements within their building."
  • With the Molekule Air Platform, we can onboard a whole fleet of air purifiers within minutes and track air quality across the property, so that all of our guests and staff can experience the benefits of truly cleaner air."
  • "Our staff has noted many comforts they've experienced since installing Molekule air purifiers and we're excited to implement the Molekule Air Platform to help us further manage the air at our facility."

SINOVAC Approved to Initiate Clinical Trial for Its Omicron Containing COVID-19 Vaccine in Chile

Retrieved on: 
Tuesday, September 6, 2022
Research, Infectious Diseases, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Valence (chemistry), COVID-19, CEO, Safety, Program, Influenza A virus subtype H1N1, WHO, NASDAQ, Vaccine, Streptococcus, R, Infection, H5N1, Instituto Butantan, HFMD, Polio, Chickenpox, Hepatitis A, Mumps, ISP, Company, Foot-and-mouth disease virus, RNA transfection, Clinical trial, Delta, EV71, Sinovac Biotech, Omicron

In this phase II randomized, double-blind, multicenter clinical trial, 826 fully vaccinated adults will be recruited.

Key Points: 
  • In this phase II randomized, double-blind, multicenter clinical trial, 826 fully vaccinated adults will be recruited.
  • Mr. Weidong Yin, the Chairman, President, and CEO of SINOVAC said, SINOVAC has made great progress collaborating with global partners in the development and manufacturing of the COVID-19 vaccine.
  • Its COVID-19 vaccine, CoronaVac, has been approved for use in more than 60 countries and regions worldwide.
  • SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities.

Darling Ingredients Inc. Announces Closing of Private Offering of $250.0 Million of Unsecured Senior Notes due 2030.

Retrieved on: 
Wednesday, August 17, 2022
Epidemic, U.S. Securities and Exchange Commission, Securities Act of 1933, DAR, Union, Poultry, Food, United Kingdom, Industry, Influenza A virus subtype H1N1, NYSE, Legislation, African swine fever virus, SARS, Failure, Sale, ASF, LLC, Security (finance), Plant, Grain, Meat, SEC Rule 144A, Cattle, Government, Disease, Compliance, COVID-19, Company, Bovine spongiform encephalopathy, DE, Pandemic, Bird Flu, Natural gas, BSE, Collagen, Severe acute respiratory syndrome, Software, Private Securities Litigation Reform Act, Regulation, Meal, Biofuel, PED, Person, Renewable energy

IRVING, Texas, Aug. 17, 2022 /PRNewswire/ -- Darling Ingredients Inc. (NYSE: DAR) ("Darling" or the "Company") today announced the closing of its private offering of $250.0 million aggregate principal amount of its unsecured senior notes due 2030 (the "add-on notes").

Key Points: 
  • IRVING, Texas, Aug. 17, 2022 /PRNewswire/ -- Darling Ingredients Inc. (NYSE: DAR) ("Darling" or the "Company") today announced the closing of its private offering of $250.0 million aggregate principal amount of its unsecured senior notes due 2030 (the "add-on notes").
  • The add-on notes bear interest at 6% per annum, payable semi-annually in arrears on June 15 and December 15 of each year, commencing on December 15, 2022.
  • Interest on the add-on notes will accrue from, and including, June 9, 2022, the first day of the current interest period for the initial notes.
  • Darling Ingredients Inc. (NYSE: DAR) is the largest publicly traded company turning food waste into sustainable products and a leading producer of renewable energy.

Darling Ingredients Inc. Announces Pricing of Private Offering of $250.0 Million of Unsecured Senior Notes due 2030

Retrieved on: 
Monday, August 15, 2022
Epidemic, U.S. Securities and Exchange Commission, Securities Act of 1933, DAR, Union, Poultry, Food, United Kingdom, Industry, Influenza A virus subtype H1N1, NYSE, Legislation, African swine fever virus, SARS, Failure, Sale, ASF, Security (finance), Plant, Grain, Meat, Compliance, SEC Rule 144A, Cattle, Government, Disease, COVID-19, Company, Bovine spongiform encephalopathy, Pandemic, Bird Flu, Natural gas, BSE, Collagen, Severe acute respiratory syndrome, Software, Private Securities Litigation Reform Act, Regulation, Meal, Biofuel, PED, Person, Renewable energy

IRVING, Texas, Aug. 15, 2022 /PRNewswire/ -- Darling Ingredients Inc. (NYSE: DAR) ("Darling" or the "Company") today announced the pricing of its private offering of $250.0 million aggregate principal amount of its 6% unsecured senior notes due 2030 (the "add-on notes").

Key Points: 
  • IRVING, Texas, Aug. 15, 2022 /PRNewswire/ -- Darling Ingredients Inc. (NYSE: DAR) ("Darling" or the "Company") today announced the pricing of its private offering of $250.0 million aggregate principal amount of its 6% unsecured senior notes due 2030 (the "add-on notes").
  • The add-on notes will be issued as additional notes under the same indenture (the "indenture") as Darling's 6% senior notes due 2030, $750.0 million in aggregate principal amount of which were issued on June 9, 2022 (the "initial notes").
  • The initial offering price to investors will be 102.0% of the principal amount thereof.
  • The offering is expected to close on or about August 17, 2022, subject to satisfaction of customary closing conditions.

Darling Ingredients Inc. Announces Private Offering of $250.0 Million of Unsecured Senior Notes

Retrieved on: 
Monday, August 15, 2022
Epidemic, U.S. Securities and Exchange Commission, Securities Act of 1933, DAR, Union, Poultry, Multimedia, Food, United Kingdom, Industry, Influenza A virus subtype H1N1, NYSE, Legislation, SARS, Failure, Sale, ASF, LLC, Security (finance), Plant, Grain, Meat, Credit, Credit agreements in South Africa, Cattle, Government, Disease, Compliance, COVID-19, Company, Bovine spongiform encephalopathy, View, DE, Pandemic, Bird Flu, Natural gas, BSE, Collagen, Severe acute respiratory syndrome, Software, Private Securities Litigation Reform Act, Regulation, Meal, PED, Person

IRVING, Texas, Aug. 15, 2022 /PRNewswire/ -- Darling Ingredients Inc. (NYSE: DAR) ("Darling" or the "Company") today announced the launch of an offering of $250.0 million in aggregate principal amount of unsecured senior notes (the "add-notes") by Darling.

Key Points: 
  • IRVING, Texas, Aug. 15, 2022 /PRNewswire/ -- Darling Ingredients Inc. (NYSE: DAR) ("Darling" or the "Company") today announced the launch of an offering of $250.0 million in aggregate principal amount of unsecured senior notes (the "add-notes") by Darling.
  • The add-on notes will be issued as additional notes under the same indenture (the "indenture") as Darling's 6% senior notes due 2030, $750.0 million in aggregate principal amount of which were issued on June 9, 2022 (the "initial notes").
  • The guarantors of the add-on notes are the same guarantors as for the initial notes and Darling's existing dollar-denominated notes.
  • Darling Ingredients Inc. (NYSE: DAR) is the largest publicly traded company turning food waste into sustainable products and a leading producer of renewable energy.

SINOVAC COVID-19 Vaccine Approved for Use in Children Above 6 months of Age in Hong Kong

Retrieved on: 
Wednesday, August 3, 2022
Biotechnology, Pharmaceutical, General Health, Health, COVID-19, Children, Infectious Diseases, Consumer, NASDAQ, Vaccine, Safety, Foot-and-mouth disease virus, Minor, Department, R, Program, Center, Health Bureau, H5N1, WHO, Scientific Committee on Antarctic Research, Infection, HFMD, Sinovac Biotech, Mumps, III, Scientific Committee on Emerging and Newly Identified Health Risks, Polio, Chickenpox, Hepatitis A, COVID-19, CoronaVac, Company, EV71, Carrie Lam as Chief Executive of Hong Kong, Vaccination, Streptococcus, COVID-19 vaccine, Ageing, Zoonosis, Influenza A virus subtype H1N1, Government

The vaccination schedule for this age group follows the same vaccination schedule of older children.

Key Points: 
  • The vaccination schedule for this age group follows the same vaccination schedule of older children.
  • SINOVAC initiated its COVID-19 vaccine (CoronaVac) phase III clinical studies among children aged 6 months to 17 years since 2021.
  • Preliminary results show the vaccine has a good safety and immunogenicity profile, with no severe adverse reaction reported 6 months after two doses of vaccination among children aged 6 months to 35 months.
  • SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities.

SINOVAC Initiates Clinical Trial for Its Quadrivalent Influenza Vaccine in Chile

Retrieved on: 
Tuesday, July 19, 2022
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious Diseases, Clinical Trials, Influenza A virus subtype H1N1, III, Chickenpox, Volunteering, Infection, WHO, Safety, Republic, Polio, Foot-and-mouth disease virus, Program, EV71, PI, NASDAQ, Sinovac Biotech, COVID-19, Company, Hepatitis A, Ageing, Mumps, Streptococcus, H5N1, Vaccine, Clinical trial, HFMD, R, Coro de la Pontificia Universidad Católica de Puerto Rico

This clinical trial aims to evaluate the immunogenicity and safety of the quadrivalent influenza vaccine among individuals aged 3 and above.

Key Points: 
  • This clinical trial aims to evaluate the immunogenicity and safety of the quadrivalent influenza vaccine among individuals aged 3 and above.
  • In total, there will be 1,600 volunteers recruited, half of whom will receive 1 dose of SINOVACs inactivated quadrivalent influenza vaccine, and the other half will receive a different quadrivalent influenza vaccine commercially available in Chile.
  • Children aged between 3 and 8 of both groups who havent received any influenza vaccine will receive 2 doses of influenza vaccine.
  • The upcoming clinical trial in Chile will provide further evidence on the efficacy and safety of SINOVACs quadrivalent influenza vaccine.

SINOVAC COVID-19 Vaccine Is Authorized for Emergency Use in Kids Aged 3-5 In Brazil

Retrieved on: 
Thursday, July 14, 2022
COVID-19, Research, Infectious Diseases, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, COVID-19, Influenza A virus subtype H1N1, Program, Pulmonology, Vaccine, H5N1, Infection, HFMD, SBP, WHO, Vaccination, Company, Hepatitis A, R, Mumps, Foot-and-mouth disease virus, Ageing, Brazilian Association of Investigative Journalism, Minor, SBI, Chickenpox, Instituto Butantan, Sinovac Biotech, Research, Association, CoronaVac, EV71, Streptococcus, To Brazil!, NASDAQ, Polio, Pharmaceutical industry, Brazilian Health Regulatory Agency, COVID-19, Research, Infectious Diseases, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science

This authorization was given under comprehensive evaluations based on analysis results from all available data on the vaccine and its use in children.

Key Points: 
  • This authorization was given under comprehensive evaluations based on analysis results from all available data on the vaccine and its use in children.
  • To assist Anvisa in evaluating the vaccine, the experts from the above institutions had access to technical materials and research data on the vaccine.
  • CoronaVac has been authorized for emergency use for adults in Brazil since January 17, 2021.
  • SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities.